Floatz logo

Chir-258

Gastric Cancer

National Cancer Centre, SingaporePhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

220 Active assets in the Gastric Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Calcium folinate pentahydrate
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Epirubicin
Rondo Therapeutics
Phase 3BB
Capecitabine
I-Mab Biopharma US Limited
Phase 3BB

View all 50 →

Same molecule, other indications

Chir-258 is also rated in:

NeoplasmsDormant
B
Indicative ·
57 / 100
View asset →
Stage III Pancreatic CancerDormant
CCC
Indicative ·
54 / 100
View asset →
Breast CancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →